Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting

MLA

T. Kühn, et al. “Using the 21-Gene Assay to Guide Adjuvant Chemotherapy Decision-Making in Early-Stage Breast Cancer: A Cost-Effectiveness Evaluation in the German Setting.” Journal of Medical Economics, vol. 16, Sept. 2012, pp. 30–40. EBSCOhost, https://doi.org/10.3111/13696998.2012.722572.

APA

T. Kühn, M Rezai, Sherko Kümmel, W J Valentine, J.U. Blohmer, W Eiermann, M Warm, A. Benkow, & K. Friedrichs. (2012). Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting. Journal of Medical Economics, 16, 30–40. https://doi.org/10.3111/13696998.2012.722572

Chicago

T. Kühn, M Rezai, Sherko Kümmel, W J Valentine, J.U. Blohmer, W Eiermann, M Warm, A. Benkow, and K. Friedrichs. 2012. “Using the 21-Gene Assay to Guide Adjuvant Chemotherapy Decision-Making in Early-Stage Breast Cancer: A Cost-Effectiveness Evaluation in the German Setting.” Journal of Medical Economics 16 (September): 30–40. doi:10.3111/13696998.2012.722572.